Clinical Trials

Searchable database of currently enrolling clinical trials
From the Editor

From the Desk of Evan Yu:

Evan Y. Yu
February 12, 2017

Recent genome sequencing data in metastatic prostate cancer have led to some significant changes in how we think about advanced disease.  Namely, the Stand Up 2 Cancer (SU2C) International Dream Team discovered that 23% of patients with metastatic castration resistant prostate cancer harbor genetic alterations in genes that lead to homologous recombination deficiency  (HRD) e.g. BRCA2, BRCA1, ATM, etc. [1]  Even more recently, our group at the University of Washington together with others have found 11.8% of patients with metastatic prostate cancer, both hormone-sensitive and castration-resistant, to harbor germline alterations in DNA repair genes. [2]  

READ MORE PREVIOUS ARTICLES

Dr. Evan Yu, MD

Evan Yu, MD

Evan Yu, a medical oncologist, treats prostate, bladder and testicular cancer, and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biologic mechanism of drug sensitivity and resistance.

Clinical Expertise

Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.

  • Professor, Department of Medical Oncology, University of Washington School of Medicine
  • Member, Fred Hutchinson Cancer Research Center
  • Assistant Fellowship Director, Hematology and Oncology Fellowship Training Program, University of Washington and Fred Hutchinson Cancer Research Center.
Search Clinical Trials by Disease

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.